Charles Ginther

5.0k citations

43 papers · 3.4k indexed · 1 hit paper · h-index 23

Impact in

Oncology top 1%
- HER2/EGFR in Cancer Research
- Cancer-related Molecular Pathways
Cancer Research top 2%
- Breast Cancer Treatment Studies

Papers in

Oncology 15
- HER2/EGFR in Cancer Research 8
- Cancer-related Molecular Pathways 3
Cancer Research 8

Co-authors: Dennis J. Slamon Judy Dering Richard S. Finn Amrita Desai Dylan Conklin Ondrej Kalous David J. Cohen Mohammad Atefi
Journals: Journal of Bacteriology (4 papers)Molecular Cancer Therapeutics (3 papers)British Journal of Cancer (3 papers)Journal of Clinical Oncology (3 papers)Cancer Research (3 papers)
Partner nations: United States Germany Ireland

In The Last Decade

Charles Ginther

43 papers receiving 3.3k citations

Hit Papers

align trajectories log scale

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro 2009 · 1.0k citations

Peers

Countries citing papers authored by Charles Ginther

Since Specialization

Citations

This map shows the geographic impact of Charles Ginther's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Ginther with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Ginther more than expected).

Fields of papers citing papers by Charles Ginther

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles Ginther. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Ginther. The network helps show where Charles Ginther may publish in the future.

Co-authors

The 25 scholars most cited alongside Charles Ginther, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Charles Ginther Line = papers co-authored together Charles Ginther links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Prognostic and Therapeutic Relevance of Molecular Subtypes in High-Grade Serous Ovarian Cancer JNCI Journal of the National Cancer Institute ·Gottfried E. Konecny, Chen Wang, Habib Hamidi, Boris Winterhoff, Kimberly R. Kalli, Judy Dering, Charles Ginther, P.Thiru Moorthy, Sean C. Dowdy, William A. Cliby, Bobbie S. Gostout, Karl C. Podratz, Gary L. Keeney, He-Jing Wang, Lynn C. Hartmann, Dennis J. Slamon, Ellen L. Goode	2014	267
2	AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53 Breast Cancer Research and Treatment ·Ondrej Kalous, Dylan Conklin, Amrita Desai, Judy Dering, Jennifer B. Goldstein, Charles Ginther, Lee Anderson, Ming Lu, Teodora Kolarova, Mark A. Eckardt, Anita Langerød, Anne‐Lise Børresen‐Dale, Dennis J. Slamon, Richard S. Finn	2013	22
3	Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro Hepatology ·Richard S. Finn, Alexey Aleshin, Judy Dering, Peter Yang, Charles Ginther, Amrita Desai, Danyun Zhao, Erika von Euw, Ronald W. Busuttil, Dennis J. Slamon	2013	43
4	POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer Gynecologic Oncology ·Beth Y. Karlan, Judy Dering, Christine Walsh, Sandra Oršulić, Jenny Lester, Lee Anderson, Charles Ginther, Marlena S. Fejzo, Dennis J. Slamon	2013	75
5	Abstract 3858: Gains in FGF19 are predictive of response to the fibroblast growth factor receptor (FGFR) small molecule tyrosine kinase inhibitor BGJ 398 in vitro Cancer Research ·Richard S. Finn, Qiuzhu Gong, Danyun Zhao, Lee Anderson, Charles Ginther, Judy Dering, Michael Shi, Diana Graus Porta, Timothy C. Ralph Gerd Leuchs, Dennis J. Slamon	2012	13
6	FOXA1 represses the molecular phenotype of basal breast cancer cells Oncogene ·Anusree Ashokan, Gürkan Bebek, Charles Ginther, 是鵜川, Kristen L. Lozada, John D. Miedler, Lee Anderson, Andrew K. Godwin, Fadi W. Abdul‐Karim, DJ Slamon, Ruth A. Keri	2012	116
7	Identification of Common Predictive Markers of In vitro Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non–Small Cell Lung Cancer Cell Lines Molecular Cancer Therapeutics ·Edward B. Garon, Richard S. Finn, Wylie Hosmer, Judy Dering, Charles Ginther, Vicki Scharnhorst, Naeimeh Kamranpour, Sharon Pitts, Amrita Desai, David Elashoff, Tim French, Paul D. Smith, Dennis J. Slamon	2010	49
8	RBM5/H37 tumor suppressor, located at the lung cancer hot spot 3p21.3, alters expression of genes involved in metastasis Lung Cancer ·Dulce Elizabeth, Guilherme Varela Barbosa, Rozi Safery, Charles Ginther, Julia Rotow, Vatsalkumar Makwana, Dennis J. Slamon	2010	29
9	Periostin promotes ovarian cancer angiogenesis and metastasis Gynecologic Oncology ·Min Zhu, Marlena S. Fejzo, Lee Anderson, Judy Dering, Charles Ginther, Lillian Ramos, Judith C. Gasson, Beth Y. Karlan, Dennis J. Slamon	2010	87
10	Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib Molecular Cancer Therapeutics ·Neil A. O’Brien, Brigid C. Browne, Lucy Chow, Yuhua Wang, Charles Ginther, Jane Arboleda, Michael J. Duffy, John Crown, Norma O’Donovan, Dennis J. Slamon	2010	249
11	PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro Breast Cancer Research ·Richard S. Finn, Judy Dering, Dylan Conklin, Ondrej Kalous, David J. Cohen, Amrita Desai, Charles Ginther, Mohammad Atefi, Isan Chen, Camilla Fowst, J Kurocká, Dennis J. Slamon Hit paper breakdown →	2009	1044
12	Activity of the multikinase inhibitor dasatinib against ovarian cancer cells British Journal of Cancer ·Gottfried E. Konecny, Rickard Glas, Judy Dering, Kanthinh Manivong, Jianfei Qi, Richard S. Finn, 张方明, James Millen, Charles Ginther, Boris Winterhoff, Guolan Gao, Joan S. Brugge, DJ Slamon	2009	81
13	The role of receptor tyrosine kinase and activated PI3K signaling in response/resistance to HER-2 targeted therapy. Cancer Research ·Charis Pericleous, Wolfgang Fricke, Lucy Chow, Charles Ginther, Cathleen R. Lammers, Jane Arboleda, MJ Duffy, John Crown, Norma O’Donovan, DJ Slamon	2009	1
14	Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells British Journal of Cancer ·Gottfried E. Konecny, Natarajan Venkatesan, Guangen Yang, Judy Dering, Charles Ginther, Richard S. Finn, Martina Rahmeh, Marlena S. Fejzo, D O Toft, Gertrud Thaer, Dennis J. Slamon, Karl C. Podratz	2008	92
15	Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro Breast Cancer Research and Treatment ·Richard S. Finn, Judy Dering, Charles Ginther, Cindy Wilson, D R Taylor, Nishan Tchekmedyian, Dennis J. Slamon	2007	330
16	Genetic variation among the Mapuche Indians from the Patagonian region of Argentina: Mitochondrial DNA sequence variation and allele frequencies of several nuclear genes Birkhäuser Basel eBooks ·Charles Ginther, Daniel Corach, Gustavo Penacino, Rey J, Francisco R. Carnese, Mara Helena Hutz, Alex Anderson, Jeanette J. Just, Francisco M. Salzano, Mary‐Claire King	1993	108
17	Intergenic suppression of stage II sporulation defects by a mutation in the major vegetative sigma factor gene (rpoD) of Bacillus subtilis Biochimie ·Ardina Budiharsana, Gargi Kashyap, 张荣光, Jamshid Arjomand, Charles Ginther, T.G. Leighton	1992	6
18	Suppression of defective-sporulation phenotypes by mutations in transcription factor genes of Bacillus subtilis Biochimie ·Gabriela Cruz-Lustre, C E Buchanan, Druck Ausrüstung Kraft-Druck GmbH, Charles Ginther, T.G. Leighton	1991	4
19	The distribution of mutagenic activity in red, rose and white wines Mutation Research/Genetic Toxicology ·辛平, Alexis Thurmond, Roberta Madej, Charles Ginther, Terrance Leighton	1989	20
20	[48] Nucleoside diphosphokinase from Salmonella typhimurium Methods in enzymology on CD-ROM/Methods in enzymology ·John L. Ingraham, Charles Ginther	1978	15

About Charles Ginther

Charles Ginther is a scholar working on Oncology, Cancer Research, Genetics, Molecular Biology and Hematology, having authored 43 papers that have together received 3.4k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (8 papers), PI3K/AKT/mTOR signaling in cancer (6 papers), Chronic Lymphocytic Leukemia Research (5 papers), Bacteriophages and microbial interactions (4 papers), Chronic Myeloid Leukemia Treatments (4 papers), Forensic and Genetic Research (3 papers), Genomics and Phylogenetic Studies (3 papers) and Cancer-related Molecular Pathways (3 papers). The work is most often cited by research in Oncology (1.8k citations), Cancer Research (683 citations), Pulmonary and Respiratory Medicine (1.1k citations), Genetics (298 citations) and Reproductive Medicine (236 citations). Charles Ginther has collaborated with scholars based in United States, Germany and Ireland. Frequent co-authors include Dennis J. Slamon, Judy Dering, Richard S. Finn, Amrita Desai, Dylan Conklin, Ondrej Kalous, David J. Cohen, Mohammad Atefi, Camilla Fowst and Isan Chen. Their work appears in journals such as Journal of Bacteriology, Molecular Cancer Therapeutics, British Journal of Cancer, Journal of Clinical Oncology and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact